We are monitoring the impact of COVID-19 on Europe Plasma Fractionation Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 2721
Share on
Share on

Europe Plasma Fractionation Market Research Report – Segmented By Product, Application, End User & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVId-19 Impact & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 2721
Pages: 145

Europe Plasma Fractionation Market Size (2021 to 2026)

The size of the Europe Plasma Fractionation Market is estimated to value USD 6.15 billion in 2021. It is projected to be growing at a CAGR of 6.10% to touch USD 8.27 billion by 2026.

Plasma fractionation is a technique for extracting plasma derivatives using a separation method. Albumin and immunoglobulins are two examples of plasma derivate available on the market. These products contain concentrated fractions of plasma protein, which are isolated from plasma obtained from many donors using fractionation. Plasma fractionation has become more popular as the older population has grown. This age group is particularly susceptible to various age-related disorders that necessitate various plasma protein therapies.

The growth of the European Plasma Fractionation Market is mainly driven by factors such as the increasing incidence of immune and bleeding disorders, the growing incidence of Alpha-1 Antitrypsin deficiency, and the rising use of immunoglobulins. Further, an increasingly aging population with related blood-related ailments is set to promote market growth. Additionally, the growing use of immunoglobulins in various therapeutic domains, expanding elderly population coupled with the rising frequency of rare diseases, and an increasing number of plasma collection sites are expected to be driving the market expansion. Furthermore, the rising prevalence of chronic neurological disorders, rheumatoid arthritis, and osteoarthritis have contributed to a rise in people who require modern therapies.

However, adverse reactions to plasma fractionation and transfer, high plasma product costs, ineffective reimbursement systems, and the rising use of recombinant alternatives are major market growth stumbling blocks.

Impact of COVID-19 on the European plasma fractionation market:

Following the WHO’s declaration of COVID-19 as a pandemic, countries worldwide implemented statewide lockdowns to enforce social separation as a preventative precaution. In every industry, this causes disruption, limits, challenges, and adjustments. The pandemic influenced the plasma fractionation business as well. The COVID-19 pandemic has resulted in a decline in blood donations and plasma collection, hating market growth due to a shortage of raw materials.

As the elective surgical procedure was postponed and care for other medical illnesses was similarly hampered, a loss in raw material supply was balanced by decreased demand for plasma derivatives at the commencement of nationwide lockdowns.

This research report on European Plasma Fractionation Market has been segmented and sub-segmented into the following categories:

By Product: 

  • Albumin
  • Immunoglobulin
  • Factor VIII
  • Protease Inhibitors

By Application: 

  • Neurology
  • Hematology
  • Rheumatology
  • Pulmonology
  • Immunology

By End User: 

  • Hospitals
  • Clinical Laboratories

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, Europe comes second in terms of market share in the global market due to greater awareness of blood-related illnesses and the speedy availability of therapy in terms of plasma fractionation. Furthermore, due to the rising occurrence of rare diseases in Europe, the region is expected to increase rapidly during the projection period. In addition, the market will benefit from the significant investments in plasma fractionation systems.

As part of developing plasma-derived therapy for treating the COVID-19 virus, the firms collaborate closely with hospitals. As a result, the hospitals and clinics segment is expected to occupy the greatest proportion of the global plasma fractionation market, based on the end-user. The expanding need for therapies for immunodeficiency disorders, the rising number of hospitals and healthcare expenditure, and the rising consumption of plasma-derived products by hospitals and clinics are all driving this segment’s rise. The market is divided into two-sector, the private sector, and the public sector.

Due to the technical advancements, the rate of diagnosis of a variety of immunological illnesses has increased. Furthermore, due to the increased number of diagnosed patients, increased genetic research for characterizing and diagnosing immunodeficiency will increase the clinical need for immunoglobulins.

The German plasma fractionation market is expected to lead the European market during the forecasting period.

KEY MARKET PLAYERS:

A few of the noteworthy companies operating in the European plasma fractionation market profiled in the report are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Product                        

                                5.1.1 Introduction           

                                5.1.2 Fractionation Process         

                                5.1.3 Immunoglobulin   

                                5.1.4 Coagulation Factor Concentrates  

                                5.1.5 Albumin   

                                5.1.6 Protease Inhibitors              

                                5.1.7  Y-o-Y Growth Analysis, By Product              

                                5.1.8  Market Attractiveness Analysis, By Product            

                                5.1.9  Market Share Analysis, By Product              

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Neurology               

                                5.2.3 Immunology           

                                5.2.4 Hematology            

                                5.2.5 Critical Care             

                                5.2.6 Pulmonology          

                                5.2.7 Hemato-Oncology               

                                5.2.8 Rheumatology       

                                5.2.9 Other Application 

                                5.2.10 Y-o-Y Growth Analysis, By Application      

                                5.2.11 Market Attractiveness Analysis, By Application    

                                5.2.12 Market Share Analysis, By Application      

                5.3 End User                      

                                5.4.1 Introduction           

                                5.4.2 Hospitals  

                                5.4.3 Clinical Laboratories            

                                5.4.4 Academic Institutes            

                                5.4.5 Y-o-Y Growth Analysis, By End User             

                                5.4.6  Market Attractiveness Analysis, By End User          

                                5.4.7  Market Share Analysis, By End User            

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Product

                                                6.1.3.3 By Application

                                                6.1.3.4 By Indication

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Product

                                                6.1.4.3 By Application

                                                6.1.4.4 By End User

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Product

                                                6.1.5.3 By Application

                                                6.1.5.4 By End User

                6.2 U.K                 

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Baxalta Incorporated                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 CSL Ltd.                        

                8.3 Grifols S.A                   

                8.4 Octapharma AG                        

                8.5 Kedrion S.p.A                            

                8.6 Bio Products Laboratory                        

                8.7 Sanquin                        

                8.8 China Biologic Products, Inc.                

                8.9 Biotest AG                  

                8.10 Laboratoire Français du Fractionnement et des Biotechnologies                      

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  2. Europe Immunoglobulin Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Coagulation Factor Concentrates Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Albumin Market, By Region, From 2021 to 2026 (USD Million)
  5. Europe Protease Inhibitors Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Other Plasma Products Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  8. Europe Neurology Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Immunology Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Hematology Market, By Region, From 2021 to 2026 (USD Million)
  11. Europe Critical Care Market, By Region, From 2021 to 2026 (USD Million)
  12. Europe Pulmonology Market, By Region, From 2021 to 2026 (USD Million)
  13. Europe Hemato-oncology Market, By Region, From 2021 to 2026 (USD Million)
  14. Europe Rheumatology Market, By Region, From 2021 to 2026 (USD Million)
  15. Europe Other Applications Market, By Region, From 2021 to 2026 (USD Million)
  16. Europe Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  17. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  18. Europe Clinical Laboratories Market, By Region, From 2021 to 2026 (USD Million)
  19. Europe Academic Institutes Market, By Region, From 2021 to 2026 (USD Million)
  20. U.K. Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  21. U.K. Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  22. U.K. Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  23. Germany Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  24. Germany Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  25. Germany Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  26. France Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  27. France Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  28. France Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  29. Italy Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  30. Italy Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  31. Italy Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)
  32. Spain Plasma Fractionation Market, By Product, From 2021 to 2026 (USD Million)
  33. Spain Plasma Fractionation Market, By Application, From 2021 to 2026 (USD Million)
  34. Spain Plasma Fractionation Market, By End User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample